Abstract
Recent studies suggest that inflammation response biomarkers are prognostic indicators of solid tumor outcomes. Here, we quantify the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in glioblastomas (GBMs), taking into consideration the role of the isocitrate dehydrogenase (IDH) mutation status. We examined 141 primary glioblastomas (pGBMs) and 25 secondary glioblastomas (sGBMs). NLRs, PLRs, and LMRs were calculated before surgery. IDH mutations were detected immunohistochemically after tumor resection, and patients' clinical outcomes were analyzed after classification into GBM, pGBM, and IDH-wild type glioblastoma (IDH-wt GBM) groups. To make comparisons, we set cutoffs for NLR, PLR and LMR of 4.0, 175.0, and 3.7, respectively. In a multivariate analysis, both NLR (HR=1.712, 95% CI 1.026-2.858, p=0.040) and PLR (HR=2.051, 95% CI 1.288-3.267, p=0.002) had independent prognostic value. While a low NLR was associated with a better prognosis only in the IDH-wt GBM group, PLR was predictive of patient survival in the GBM, pGBM, and IDH-wt GBM groups. By contrast, LMR exhibited no prognostic value for any of the 3 types of GBM.
Highlights
Glioblastomas are the most common brain malignancies, accounting for 15.1% of the total central nervous system tumors [1]
We found that neutrophil-to-lymphocyte ratio (NLR) had no significant prognostic value for patients with glioblastomas [12.80 months vs. 6.03 months; p=0.172, Figure 1a] and those in the primary glioblastomas (pGBMs) group [13.30 months vs. 6.03 months; p=0.104, Figure 1b]
We first assessed the prognostic value of NLR, platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in glioblastomas, taking into account isocitrate dehydrogenase (IDH) mutation status
Summary
Glioblastomas are the most common brain malignancies, accounting for 15.1% of the total central nervous system tumors [1]. Glioblastomas are classified as either primary glioblastomas (pGBMs) or secondary glioblastomas (sGBMs), which develop from lower-grade gliomas [2]. The development of gliomas, in particular, is closely associated with inflammation status and immune response [12, 13]. A high NLR and PLR and low LMR are closely associated with a poor prognosis in solid malignancies, including gastrointestinal tumors, prostate cancer, and lung cancer [14,15,16,17,18,19]. While a low preoperative NLR closely correlates with lower glioma grade and better clinical outcome [20,21,22], there are no published data assessing the role of PLR or LMR in gliomas. The characteristics of NLRs, PLRs, and LMRs are described here, taking into consideration IDH mutation status
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
